6533b7d0fe1ef96bd125a3df

RESEARCH PRODUCT

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

M.l. ChretienMarie SebertYasmine ChaitPierre FenauxKamel LaribiEric SolaryThorsten BraunUwe PlatzbeckerGruson BNorbert VeyOdile Beyne-rauzySophie ParkSylvain PilorgeLaurence LegrosRaphael ItzyksonPierre-yves DumasSahnes LRomain GuiezeCelia SalanoubatJean-baptiste MicolMatthieu DuchmannPierre Hirsch

subject

OncologyAdultMalemedicine.medical_specialtyAntimetabolites AntineoplasticeducationAzacitidineChronic myelomonocytic leukemiaDecitabine03 medical and health sciences0302 clinical medicineMyelodysplastic–myeloproliferative diseaseshemic and lymphatic diseasesInternal medicinemedicineHumansLetter to the Editorhealth care economics and organizationsAgedHematologybusiness.industryMyelodysplastic syndromesTranslational biologyfood and beveragesLeukemia Myelomonocytic Chronic[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyDNA MethylationMiddle Agedmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesSurvival Analysis3. Good healthResponse assessmentLeukemiaTreatment OutcomeOncology030220 oncology & carcinogenesisMyelodysplastic SyndromesImmunologyAzacitidineFemalebusiness030215 immunologymedicine.drug

description

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

10.1038/bcj.2017.41https://hal.science/hal-01655936